Novo Nordisk A/S B

Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
  • TickerNOVO B
  • ISINDK0060534915
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

With a more favourable environment, NOVO NORDISK A/S improves to Slightly Positive

NOVO NORDISK A/S (DK), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date October 8, 2019, the closing price was DKK 350.60 and its potential was estimated at DKK 381.82.

Martial Descoutures ...
  • Oussema Denguir

Novo Nordisk : Rybelsus is approved in the US.

>The FDA approves oral semaglutide (Rybelsus) - As expected, last Friday the FDA approved oral semaglutide, which will be sold under the brand name Rybelsus, in patients with type 2 diabetes. In view of the results of the PIONEER programme, approval of the drug was a mere formality and the presence of the warning box is in line with Ozempic. All of the clinical results presented for the Novo Nordisk molecule were convincing. The 10 Phase III trials showed on average a...

Martial Descoutures ...
  • Oussema Denguir

Novo Nordisk : Rybelsus est approuvé aux Etats-Unis

>La FDA approuve semaglutide oral (Rybelsus) - Comme attendu, la FDA a approuvé vendredi dernier semaglutide oral, qui aura pour nom commercial Rybelsus, chez les patients ayant un diabète de type 2. A la vue des résultats du programme PIONEER, l’approbation du médicament est une simple formalité et la présence de la warning box reste en ligne avec Ozempic. L’ensemble des résultats cliniques présenté pour le composé de Novo Nordisk a été probant. Les 10 études de phas...

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK420.00) - A new playing field is wide open

The FDA just approved Novo Nordisk’s oral version of the GLP-1 semaglutide (now named Rybelsus) based on the PIONEER studies, without any unexpected comments on the label. We continue to see Rybelsus as a very important addition to the GLP-1 franchise. GLP-1 accounts for more than 1/3 of our target price. We reiterate our BUY recommendation and have raised our target price from DKK410 to DKK420.

Team Pharma

ODDO : Dans un contexte volatil, nous privilégions AstraZeneca et Novartis

Depuis notre étude du 6 mai dernier « favoriser l’innovation et le recentrage Pharma », le Stoxx 600 Healthcare a progressé de 8.7% vs -0.4% pour le Stoxx 600. Cette performance est notamment expliquée par des publications du S1 de bonne facture. Cependant tributaire des annonces de reformes potentielles de la santé américaine, nous considérons toujours que le secteur devrait rester volatil dans ces prochains mois. Nous maintenons dans ce contexte notre préférence pour AstraZenec...

Team Pharma

ODDO : In a volatile context, we favour AstraZeneca and Novartis

Since the publication of our “Favour innovation and refocusing on pharma” report on the 6 May 2019, the Stoxx 600 Healthcare index has turned in a performance of +8.7% vs -0.4% for the Stoxx 600. This performance is notably attributable to a good set of H1 2019 results publications. However, as the pharma sector is dependent on announcements concerning the potential reforms of the US healthcare system, we think it is likely to remain volatile in the coming months. Against this ba...

1 director sold

A director at Novo Nordisk AS sold 18,000 shares at 335.894DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Alain William ...
  • Bruno Cavalier
  • Charles Lepetitpas
  • François Maury
  • Georges Dieng
  • Jean Sassus
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Pierre Tegner
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/23/2019

...

Alain William ...
  • Bruno Cavalier
  • Charles Lepetitpas
  • François Maury
  • Georges Dieng
  • Jean Sassus
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Pierre Tegner
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 23/09/2019

...

Mattias Holmberg ...
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Håkon Astrup ...
  • Jørgen Lian
  • Karl-Johan Bonnevier
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Benoit Valleaux ...
  • Emira Sagaama
  • Harald Eggeling
  • Jean Sassus
  • Khaled Ben Amor
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/09/2019

...

With a more favourable environment, NOVO NORDISK A/S improves to Slightly Positive

NOVO NORDISK A/S (DK), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date October 8, 2019, the closing price was DKK 350.60 and its potential was estimated at DKK 381.82.

Nurhayati Wan

Novo Nordisk

Nurhayati Wan

Novo Nordisk

Nurhayati Wan

Novo Nordisk

Nurhayati Wan

Novo Nordisk

MarketLine Department

F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report

F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report Summary F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights F. Hoffmann-La Roche Ltd (Roche or 'the company') is one of the leading research-focused healthcare groups in the world. It is involved in the discovery, development and commercialization of innovative therapeut...

MarketLine Department

F. Hoffmann-La Roche Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's F. Hoffmann-La Roche Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by F. Hoffmann-La Roche Ltd since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive a...

MarketLine Department

Antares Pharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Antares Pharma, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Antares Pharma, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage...

Expert Corporate Governance Service (ECGS)

Novo Nordisk, March 21 2019

In general, Novo Nordisk is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 5.3 (b), it is proposed to newly appoint Ms. Laurence Debroux as Member of the board of directors. Although Ms. Debroux would be considered independent in accordance with provision 3.2.1 of the Danish Recommendations on Corporate Governance, ECGS has concerns over her aggregate time commitments. Ms. Debroux is currently already serving as CFO of Heineken N.V. (listed) and non-executive director of Exor N.V. (listed). Taking into account he...

Novo Nordisk – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

The U.S. has continued to separate itself from broad emerging market and developed international indexes. Thankfully, one positive is that MSCI EM and MSCI EAFE have been able to stabilize from a price perspective despite relative strength weakness vs. MSCI ACWI... see charts below. In today's report we scour the globe for attractive investments in an environment where selectivity is key. • Emerging markets. There is still not much to like about broad EM as the MSCI Emerging Markets index has remained weak following price and relative strength breakdowns. Remain underweight broad EM and be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch